Company’s 36-month beta value is 1.94.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMNM is 76.80M, and currently, short sellers hold a 16.30% ratio of that floaft. The average trading volume of IMNM on July 10, 2025 was 1.05M shares.
IMNM) stock’s latest price update
Immunome Inc (NASDAQ: IMNM)’s stock price has gone rise by 3.98% in comparison to its previous close of $8.55, however, the company has experienced a 5.02% increase in its stock price over the last five trading days. businesswire.com reported 2025-07-03 that BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 125,500 shares of common stock to 8 new employees under the Company’s 2024 Inducement.
IMNM’s Market Performance
Immunome Inc (IMNM) has seen a 5.02% rise in stock performance for the week, with a -2.63% decline in the past month and a 51.19% surge in the past quarter. The volatility ratio for the week is 5.66%, and the volatility levels for the past 30 days are at 5.82% for IMNM.. The simple moving average for the past 20 days is -0.88% for IMNM’s stock, with a -12.24% simple moving average for the past 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Lake Street repeating the rating for IMNM by listing it as a “Buy.” The predicted price for IMNM in the upcoming period, according to Lake Street is $23 based on the research report published on April 02, 2025 of the current year 2025.
Stephens, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $30. The rating they have provided for IMNM stocks is “Overweight” according to the report published on November 08th, 2024.
Piper Sandler gave a rating of “Overweight” to IMNM, setting the target price at $27 in the report published on May 31st of the previous year.
IMNM Trading at 2.69% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.11% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from BIENAIME JEAN JACQUES, who purchase 5,000 shares at the price of $9.38 back on Jun 03 ’25. After this action, BIENAIME JEAN JACQUES now owns 36,415 shares of Immunome Inc, valued at $46,900 using the latest closing price.
BIENAIME JEAN JACQUES, the Director of Immunome Inc, purchase 7,800 shares at $7.78 during a trade that took place back on Mar 25 ’25, which means that BIENAIME JEAN JACQUES is holding 31,415 shares at $60,684 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -19.94 for the present operating margin
- 1.0 for the gross margin
The net margin for Immunome Inc stands at -18.75. The total capital return value is set at -0.7. Equity return is now at value -69.21, with -61.93 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -32.01.
Currently, EBITDA for the company is -151.35 million with net debt to EBITDA at 1.44. When we switch over and look at the enterprise to sales, we see a ratio of 47.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.49.
Conclusion
In a nutshell, Immunome Inc (IMNM) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
